
United States
Securities and Exchange Commission
Washington, D.C. 20549

SCHEDULE 13D
(Rule 13d-101)

Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to
§ 240.13d-2(a)

Under the Securities Exchange Act of 1934
(Amendment No. 20)*

Medpace Holdings, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

58506Q109
(CUSIP Number)

August J. Troendle
c/o Medpace Holdings, Inc.
5375 Medpace Way
Cincinnati, OH 45227
Tel: (513) 579-9911

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 26, 2024
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES OF REPORTING PERSONS	
	August J. Troendle	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	SOURCE OF FUNDS	
	PF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
	<input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION	
	United States	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER
		806,643
	8	SHARED VOTING POWER
		5,183,019
	9	SOLE DISPOSITIVE POWER
		806,643
	10	SHARED DISPOSITIVE POWER
		5,183,019
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	6,496,852	
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	
	<input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
	20.8%	
14	TYPE OF REPORTING PERSON	
	IN	

1	NAMES OF REPORTING PERSONS	
	Medpace Investors, LLC	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="checkbox"/> (b) <input checked="" type="checkbox"/>	
3	SEC USE ONLY	
4	SOURCE OF FUNDS	
	OO	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
	<input type="checkbox"/>	
6	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER
		0
	8	SHARED VOTING POWER
		5,183,019
	9	SOLE DISPOSITIVE POWER
		0
	10	SHARED DISPOSITIVE POWER
		5,183,019
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	5,183,019	
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES	
	<input type="checkbox"/>	
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
	16.6%	
14	TYPE OF REPORTING PERSON	
	OO (Limited liability company)	

This Amendment No. 20 to the Schedule 13D (this “Amendment No. 20”) amends and supplements the Statement on Schedule 13D filed with the United States Securities and Exchange Commission on August 26, 2016, as amended by Amendment No. 1 filed on August 8, 2018, Amendment No. 2 filed on October 2, 2018, Amendment No. 3 filed on February 6, 2019, Amendment No. 4 filed on August 5, 2019, Amendment No. 5 filed on August 7, 2019, Amendment No. 6 filed on August 15, 2019, Amendment No. 7 filed on September 17, 2019, Amendment No. 8 filed on May 8, 2020, Amendment No. 9 filed on July 31, 2020, Amendment No. 10 filed on August 14, 2020, Amendment No. 11 filed on December 21, 2020, Amendment No. 12 filed on April 21, 2021, Amendment No. 13 filed on September 1, 2021, Amendment No. 14 filed on December 23, 2021, Amendment No. 15 filed on July 6, 2022, Amendment No. 16 filed on September 13, 2022, Amendment No. 17 filed September 21, 2022, Amendment No. 18 filed September 22, 2023, and Amendment No. 19 filed December 5, 2023 (collectively, the “Statement”), relating to the common stock (the “Common Stock”), of Medpace Holdings, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meaning set forth in the Statement.

Item 5. Interest in Securities of the Issuer

Items 5(a) - (b) of the Statement are amended and restated in their entirety as follows: (a) - (b): See Items 7 – 13 of the cover pages above.

Item 5(c) of the Statement is amended and supplemented by inserting the following information:

(c): Medpace Investors, LLC (“MPI”) has sold shares in open market transactions executed pursuant to limit orders between February 16, 2024 and February 27, 2024 as follows:

<u>Trade Date</u>	<u>Shares Sold</u>	<u>Price Per Share</u>
02/16/2024	15,742	\$390.81 ⁽¹⁾
02/16/2024	21,586	\$391.42 ⁽²⁾
02/16/2024	5,794	\$392.48 ⁽³⁾
02/16/2024	1,757	\$393.76 ⁽⁴⁾
02/16/2024	5,121	\$394.49 ⁽⁵⁾
02/20/2024	6,136	\$385.27 ⁽⁶⁾
02/20/2024	3,268	\$386.21 ⁽⁷⁾
02/20/2024	2,624	\$387.60 ⁽⁸⁾
02/20/2024	1,859	\$388.52 ⁽⁹⁾
02/20/2024	101	\$389.12 ⁽¹⁰⁾
02/21/2024	3,199	\$380.54 ⁽¹¹⁾
02/21/2024	4,058	\$381.38 ⁽¹²⁾
02/21/2024	6,724	\$382.52 ⁽¹³⁾
02/21/2024	10,147	\$383.44 ⁽¹⁴⁾
02/21/2024	3,691	\$384.51 ⁽¹⁵⁾
02/21/2024	3,110	\$385.44 ⁽¹⁶⁾
02/21/2024	5,083	\$386.18 ⁽¹⁷⁾
02/22/2024	1,540	\$391.40 ⁽¹⁸⁾
02/22/2024	1,611	\$392.35 ⁽¹⁹⁾
02/22/2024	21,028	\$393.39 ⁽²⁰⁾
02/22/2024	17,672	\$394.41 ⁽²¹⁾
02/22/2024	14,578	\$395.17 ⁽²²⁾
02/22/2024	5,806	\$396.49 ⁽²³⁾
02/22/2024	4,819	\$397.36 ⁽²⁴⁾
02/22/2024	17,676	\$398.27 ⁽²⁵⁾
02/22/2024	9,666	\$399.29 ⁽²⁶⁾
02/22/2024	4,873	\$400.28 ⁽²⁷⁾
02/22/2024	731	\$401.28 ⁽²⁸⁾
02/23/2024	452	\$396.77 ⁽²⁹⁾
02/23/2024	1,883	\$397.88 ⁽³⁰⁾
02/23/2024	7,273	\$398.75 ⁽³¹⁾
02/23/2024	39,444	\$399.79 ⁽³²⁾
02/23/2024	31,718	\$400.57 ⁽³³⁾
02/23/2024	15,784	\$401.81 ⁽³⁴⁾
02/23/2024	3,446	\$402.25 ⁽³⁵⁾
02/26/2024	76	\$397.98
02/26/2024	436	\$399.26 ⁽³⁶⁾
02/26/2024	798	\$400.81 ⁽³⁷⁾
02/26/2024	22,033	\$401.59 ⁽³⁸⁾
02/26/2024	21,845	\$402.57 ⁽³⁹⁾
02/26/2024	8,653	\$403.42 ⁽⁴⁰⁾

- (38) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$401.02 to \$401.97. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (39) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$401.98 to \$402.975. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (40) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$402.98 to \$403.95. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (41) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$403.98 to \$404.92. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (42) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$405.00 to \$405.72. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (43) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$398.84 to \$399.82. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (44) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$399.85 to \$400.83. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (45) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$400.84 to \$401.80. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (46) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$401.85 to \$402.825. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (47) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$402.84 to \$403.78. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- (48) The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$403.91 to \$404.17. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

Item 7. Materials to be Filed as Exhibits

<u>Exhibit Number</u>	<u>Description</u>
1	Joint Filing Agreement*
2	Registration Rights Agreement*

* Filed in the Statement.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 28, 2024

/s/ August J. Troendle

August J. Troendle

Medpace Investors, LLC

/s/ August J. Troendle

Name: August J. Troendle

Title: Sole Manager